SPIROLAXIMES FOR USE IN THE TREATMENT OF PATHOLOGIES THAT RESPOND TO PPAR-.GAMMA. RECEPTOR ACTIVATION

摘要

This invention features the use of the spirolaxine of formula (I) for the treatment of those pathologies responding to the activation of the PPAR.UPSILON. receptor, such as the Type 2 insulin-resistant diabetes. This invention also features a pharmaceutical composition in which the spirolaxine of formula (I) acts as active principle in association with the all-trans retinoic acid of formula (II) for the treatment of those pathologies responding to the activation of the PPAR.UPSILON. receptor, such as the acute malignant haemopathies.